Achieved $479.0 million in AYVAKIT® (avapritinib) global net product revenues in 2024, including $144.1 million in the fourth quarter -- -- Anticipate global AYVAKIT ...
Blueprint Medicines (BPMC) sees strong AYVAKIT growth, 2025 revenue guidance at $680M-$710M. Discover insights on their market expansion & $2B 2030 vision.
This concealer is the best I've tried so far. My skin is textured and tends to be dry in the colder months, so I appreciate ...
Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...
10h
CPS Wood Products, a Canada-based lumber manufacturer, acknowledges the skepticism with its innovation and planet-forward ...
Interior designers discuss how they’re preparing for tariff price hikes, using strategies like vintage sourcing, side hustles ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback